Collegium Pharmaceutical Company Profile (NASDAQ:COLL)

About Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical logoCollegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:COLL
  • CUSIP: N/A
  • Web: www.collegiumpharma.com
Capitalization:
  • Market Cap: $255.11 million
  • Outstanding Shares: 29,458,000
Average Prices:
  • 50 Day Moving Avg: $9.44
  • 200 Day Moving Avg: $13.92
  • 52 Week Range: $7.37 - $20.55
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.71
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.88 million
  • Price / Sales: 65.75
  • Book Value: $3.88 per share
  • Price / Book: 2.23
Profitability:
  • EBIDTA: ($101,250,000.00)
  • Return on Equity: -80.20%
  • Return on Assets: -67.31%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 4.29%
  • Quick Ratio: 4.22%
Misc:
  • Average Volume: 435,543 shs.
  • Beta: 0.25
  • Short Ratio: 10.97
 

Frequently Asked Questions for Collegium Pharmaceutical (NASDAQ:COLL)

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical Inc (NASDAQ:COLL) issued its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.19. The business earned $2.17 million during the quarter, compared to the consensus estimate of $3.55 million. View Collegium Pharmaceutical's Earnings History.

Where is Collegium Pharmaceutical's stock going? Where will Collegium Pharmaceutical's stock price be in 2017?

4 brokers have issued twelve-month price targets for Collegium Pharmaceutical's stock. Their predictions range from $22.00 to $25.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $23.75 in the next twelve months. View Analyst Ratings for Collegium Pharmaceutical.

Are investors shorting Collegium Pharmaceutical?

Collegium Pharmaceutical saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 4,694,850 shares, an increase of 8.9% from the March 31st total of 4,310,053 shares. Based on an average trading volume of 449,900 shares, the days-to-cover ratio is presently 10.4 days.

Who are some of Collegium Pharmaceutical's key competitors?

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Who owns Collegium Pharmaceutical stock?

Collegium Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (7.34%), Frazier Management LLC (6.41%), TPG Group Holdings SBS Advisors Inc. (4.74%), Morgan Stanley (3.01%), Vanguard Group Inc. (2.74%) and Massachusetts Financial Services Co. MA (2.17%). Company insiders that own Collegium Pharmaceutical stock include John A Fallon and Paul Brannelly. View Institutional Ownership Trends for Collegium Pharmaceutical.

Who sold Collegium Pharmaceutical stock? Who is selling Collegium Pharmaceutical stock?

Collegium Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, ProShare Advisors LLC and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Collegium Pharmaceutical.

Who bought Collegium Pharmaceutical stock? Who is buying Collegium Pharmaceutical stock?

Collegium Pharmaceutical's stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Massachusetts Financial Services Co. MA, Leucadia National Corp, Eventide Asset Management LLC, Wells Fargo & Company MN, Vanguard Group Inc., Highbridge Capital Management LLC and Pier Capital LLC. Company insiders that have bought Collegium Pharmaceutical stock in the last two years include John A Fallon and Paul Brannelly. View Insider Buying and Selling for Collegium Pharmaceutical.

How do I buy Collegium Pharmaceutical stock?

Shares of Collegium Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Collegium Pharmaceutical stock cost?

One share of Collegium Pharmaceutical stock can currently be purchased for approximately $8.66.

Analyst Ratings

Consensus Ratings for Collegium Pharmaceutical (NASDAQ:COLL) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.75 (174.25% upside)

Analysts' Ratings History for Collegium Pharmaceutical (NASDAQ:COLL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017Jefferies Group LLCReiterated RatingBuy$24.00 -> $22.00LowView Rating Details
5/11/2017Needham & Company LLCLower Price TargetBuy -> Buy$28.00 -> $25.00HighView Rating Details
10/12/2016Piper Jaffray CompaniesSet Price TargetBuy$23.00N/AView Rating Details
9/13/2016GabelliInitiated CoverageBuy$25.00N/AView Rating Details
3/15/2016Janney Montgomery ScottInitiated CoverageBuy$25.00N/AView Rating Details
2/19/2016William BlairInitiated CoverageOutperform$35.00N/AView Rating Details
(Data available from 5/22/2015 forward)

Earnings

Earnings History for Collegium Pharmaceutical (NASDAQ:COLL)
Earnings by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Earnings History by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.98)($0.79)$3.55 million$2.17 millionViewN/AView Earnings Details
3/9/2017Q4 2016($1.07)($1.02)$1.79 million$1.30 millionViewListenView Earnings Details
11/10/2016Q3 2016($1.09)($1.13)$1.00 million$0.41 millionViewListenView Earnings Details
8/10/2016Q2($0.76)($1.05)$0.16 millionViewListenView Earnings Details
5/10/2016Q1($0.60)($0.68)ViewListenView Earnings Details
3/15/2016Q415($0.45)($0.46)ViewListenView Earnings Details
11/12/2015Q315($0.30)($0.46)ViewListenView Earnings Details
8/12/2015Q215($0.26)($0.45)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Collegium Pharmaceutical (NASDAQ:COLL)
2017 EPS Consensus Estimate: ($3.19)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.89)($0.89)($0.89)
Q2 20172($0.81)($0.74)($0.78)
Q3 20172($0.79)($0.71)($0.75)
Q4 20172($0.93)($0.62)($0.78)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Collegium Pharmaceutical (NASDAQ:COLL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Collegium Pharmaceutical (NASDAQ:COLL)
Insider Ownership Percentage: 37.93%
Institutional Ownership Percentage: 56.60%
Insider Trades by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Insider Trades by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Paul BrannellyInsiderBuy10,000$9.18$91,800.00View SEC Filing  
8/12/2016John A FallonDirectorBuy2,375$10.59$25,151.25View SEC Filing  
5/12/2015John Gordon FreundDirectorBuy150,000$12.00$1,800,000.00View SEC Filing  
5/12/2015Longitude Capital Partners, LlMajor ShareholderBuy200,000$12.00$2,400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Collegium Pharmaceutical (NASDAQ:COLL)
Latest Headlines for Collegium Pharmaceutical (NASDAQ:COLL)
Source:
DateHeadline
americanbankingnews.com logoCollegium Pharmaceutical Inc (COLL) Insider Paul Brannelly Acquires 10,000 Shares
www.americanbankingnews.com - May 15 at 7:52 PM
prnewswire.com logoHow These Generic Drugs Stocks are Faring? -- Akorn, Collegium Pharma, Momenta Pharma, and Diplomat Pharmacy
www.prnewswire.com - May 15 at 12:03 PM
americanbankingnews.com logoQ2 2017 Earnings Estimate for Collegium Pharmaceutical Inc (COLL) Issued By Jefferies Group
www.americanbankingnews.com - May 15 at 7:58 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Collegium Pharmaceutical Inc (COLL) Boosted by William Blair
www.americanbankingnews.com - May 15 at 7:58 AM
americanbankingnews.com logoCollegium Pharmaceutical Inc (COLL) Price Target Cut to $25.00 by Analysts at Needham & Company LLC
www.americanbankingnews.com - May 14 at 12:32 AM
americanbankingnews.com logoCollegium Pharmaceutical Inc (COLL) Earns "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - May 11 at 9:02 PM
americanbankingnews.com logoCollegium Pharmaceutical Inc (COLL) Issues Earnings Results
www.americanbankingnews.com - May 11 at 9:00 PM
reuters.com logoBRIEF-Collegium reports Q1 loss per share $0.79
www.reuters.com - May 11 at 2:39 AM
globenewswire.com logoCollegium Reports First Quarter Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - May 10 at 9:38 PM
americanbankingnews.com logoCollegium Pharmaceutical Inc (COLL) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 10 at 8:56 PM
finance.yahoo.com logoInvestor Network: Collegium Pharmaceutical, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 4:37 PM
finance.yahoo.com logoCollegium Reports First Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 4:37 PM
finance.yahoo.com logoCollegium Pharmaceutical posts 1Q loss
finance.yahoo.com - May 10 at 4:37 PM
americanbankingnews.com logoCollegium Pharmaceutical (COLL) Getting Somewhat Positive Press Coverage, Report Shows
www.americanbankingnews.com - May 3 at 5:04 PM
finance.yahoo.com logoCollegium to Host Conference Call to Discuss First Quarter 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - May 3 at 4:24 PM
americanbankingnews.com logoShort Interest in Collegium Pharmaceutical Inc (COLL) Expands By 8.9%
www.americanbankingnews.com - April 30 at 12:25 AM
americanbankingnews.com logoCollegium Pharmaceutical (COLL) Earning Somewhat Favorable News Coverage, Study Shows
www.americanbankingnews.com - April 29 at 2:02 PM
americanbankingnews.com logoZacks: Brokerages Expect Collegium Pharmaceutical Inc (COLL) Will Post Quarterly Sales of $3.55 Million
www.americanbankingnews.com - April 29 at 7:58 AM
americanbankingnews.com logo-$0.97 EPS Expected for Collegium Pharmaceutical Inc (COLL) This Quarter
www.americanbankingnews.com - April 28 at 12:50 AM
americanbankingnews.com logoNeedham & Company LLC Reiterates "Buy" Rating for Collegium Pharmaceutical Inc (COLL)
www.americanbankingnews.com - April 25 at 12:20 PM
americanbankingnews.com logoCollegium Pharmaceutical (COLL) Earns News Impact Rating of 0.12
www.americanbankingnews.com - April 23 at 5:05 PM
americanbankingnews.com logoCollegium Pharmaceutical (COLL) Given News Sentiment Score of 0.31
www.americanbankingnews.com - April 20 at 4:50 PM
finance.yahoo.com logoCollegium to Present at the 42nd Annual Deutsche Bank Healthcare Conference
finance.yahoo.com - April 20 at 4:34 PM
americanbankingnews.com logoCollegium Pharmaceutical Inc (COLL) Receives "Buy" Rating from Needham & Company LLC
www.americanbankingnews.com - April 19 at 7:28 PM
finance.yahoo.com logoCollegium Announces Appointment of Steven Passik, PhD, as Vice President, Scientific Affairs, Education and Policy
finance.yahoo.com - April 7 at 9:07 AM
streetinsider.com logoCollegium Pharma (COLL) Confirms Managed Care Coverage Expansion for Xtampza ER for Medicare Part D - StreetInsider.com
www.streetinsider.com - April 3 at 9:53 PM
finance.yahoo.com logoBlog Coverage BioDelivery Extends its Patent Portfolio; Acquires Extended Patents for BELBUCA, BUNAVIL, and ONSOLIS
finance.yahoo.com - April 3 at 4:52 PM
reuters.com logoBRIEF-Collegium Pharmaceutical announces expanded managed care coverage
www.reuters.com - April 3 at 4:52 PM
finance.yahoo.com logoCollegium Announces Expanded Managed Care Coverage for Xtampza ER for Medicare Part D Patients
finance.yahoo.com - April 3 at 4:52 PM
businesswire.com logoPixarBio Corporation’s CEO Frank Reynolds to Discuss Non-Opiate/Opioid NeuroRelease on the Pain and Addiction Panel at the 2017 MassBio Annual Meeting in Cambridge, MA on ...
www.businesswire.com - March 30 at 4:51 PM
finance.yahoo.com logoCollegium to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 28 at 4:11 PM
americanbankingnews.com logoGabelli Comments on Collegium Pharmaceutical Inc's FY2017 Earnings (COLL)
www.americanbankingnews.com - March 27 at 9:53 AM
americanbankingnews.com logoCollegium Pharmaceutical Inc (COLL) Given a $24.00 Price Target by Jefferies Group LLC Analysts
www.americanbankingnews.com - March 27 at 12:58 AM
capitalcube.com logoCollegium Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : COLL-US : March 21, 2017
us.rd.yahoo.com - March 21 at 11:56 AM
finance.yahoo.com logoCollegium Announces Scientific Presentation at American Academy of Pain Medicine 2017 Meeting
finance.yahoo.com - March 16 at 5:47 PM
finance.yahoo.com logoCOLLEGIUM PHARMACEUTICAL, INC Financials
finance.yahoo.com - March 16 at 5:47 PM
reuters.com logoBRIEF-Collegium Pharma enters controlled equity offering sales agreement
www.reuters.com - March 13 at 12:29 PM
biz.yahoo.com logoCOLLEGIUM PHARMACEUTICAL, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
biz.yahoo.com - March 13 at 12:29 PM
biz.yahoo.com logoCOLLEGIUM PHARMACEUTICAL, INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 10 at 5:27 PM
seekingalpha.com logoCollegium Pharmaceutical's (COLL) CEO Mike Heffernan on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 10 at 10:19 AM
reuters.com logoBRIEF-Collegium Q4 loss per share $1.02
www.reuters.com - March 9 at 5:00 PM
biz.yahoo.com logoQ4 2016 Collegium Pharmaceutical Inc Earnings Release - Before Market Open
biz.yahoo.com - March 9 at 5:00 PM
finance.yahoo.com logoCollegium Reports Fourth Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - March 9 at 5:00 PM
biz.yahoo.com logoCOLLEGIUM PHARMACEUTICAL, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
biz.yahoo.com - March 9 at 5:00 PM
biz.yahoo.com logoCollegium Pharmaceutical Inc Earnings Call scheduled for 4:30 pm ET today
biz.yahoo.com - March 9 at 5:00 PM
finance.yahoo.com logoBioDelivery Sciences to Present at the 29th Annual ROTH Conference
finance.yahoo.com - March 8 at 10:03 AM
finance.yahoo.com logoTrevi Therapeutics Names Michael Heffernan to Its Board of Directors - Yahoo Finance
finance.yahoo.com - March 7 at 12:17 PM
finance.yahoo.com logoCollegium to Host Conference Call to Discuss 2016 Financial Results and Provide Corporate Update
finance.yahoo.com - February 28 at 4:38 PM
bizjournals.com logoBiocom Appoints New Officers and Members to Board of Directors
www.bizjournals.com - February 27 at 4:24 PM
streetinsider.com logoCollegium Pharma (COLL) Reports Positive Topline Results of Trial Evaluating the Oral Abuse of Xtampza ER - StreetInsider.com
www.streetinsider.com - February 2 at 4:46 PM

Social

Collegium Pharmaceutical (COLL) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by MarketBeat.com Staff